Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Equity Ratio (2016 - 2025)

Protalix BioTherapeutics has reported Equity Ratio over the past 16 years, most recently at 0.59 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.59 for Q4 2025, changed 0.49% from a year ago — trailing twelve months through Dec 2025 was 0.59 (changed 0.49% YoY), and the annual figure for FY2025 was 0.59, changed 0.49%.
  • Equity Ratio for Q4 2025 was 0.59 at Protalix BioTherapeutics, down from 0.64 in the prior quarter.
  • Over the last five years, Equity Ratio for PLX hit a ceiling of 0.64 in Q3 2025 and a floor of 0.2 in Q3 2022.
  • Median Equity Ratio over the past 5 years was 0.32 (2024), compared with a mean of 0.25.
  • Biggest five-year swings in Equity Ratio: plummeted 8057.7% in 2022 and later soared 2089.58% in 2024.
  • Protalix BioTherapeutics' Equity Ratio stood at 0.08 in 2021, then crashed by 132.77% to 0.19 in 2022, then soared by 308.46% to 0.4 in 2023, then skyrocketed by 48.04% to 0.59 in 2024, then dropped by 0.49% to 0.59 in 2025.
  • The last three reported values for Equity Ratio were 0.59 (Q4 2025), 0.64 (Q3 2025), and 0.64 (Q2 2025) per Business Quant data.